You are viewing Sub-Saharan Africa

Choose Your Location:
    • United States
    • Canada
    • Mexico
  • South America
  • EMENA
  • Sub-Saharan Africa
  • Russia
  • South Asia
  • Asia Pacific
  • China
  • Global

Choose Your Location:

north-america-noactive usa-active canada-active mexico-active
  • United States
  • Canada
  • Mexico
north-america-noactive north-america-active
South America
north-america-noactive north-america-active
EMENA
Africa Africa
Sub-Saharan Africa
Russia Russia
Russia
South Asia South Asia
South Asia
Asia Asia
Asia Pacific
China China
China
global-site-noactive global-site-active
Global

English

COLI-VAC™

Product Overview

COLI-VAC™ is an inactivated heptavalent vaccine to prevent systemic E. Coli infections in commercial poultry.

Target Species

Chickens.

Immunocompetence Poultry

E. coli infections in Poultry Production

Avian colibacillosis is a systemic disease caused by avian pathogenic Escherichia coli (APEC), a harmful Gram negative bacteria triggering diverse local and systemic infections in poultry. The clinical findings associated to APEC infection in poultry include: perihepatitis, airsacculitis, pericarditis, egg peritonitis, salphingitis, coligranuloma, omphalitis, cellulitis, and osteomyelitis/arthritis.2

Colibacillosis is one of the leading causes of morbidity in poultry production, causing irreparable losses associated to:3,4,5

  • Decreased protein production (2% decline in live weight, 2.7% deterioration in feed conversion ratio).
  • Decreased egg production (up to 20%).
  • Decreased hatching rates.
  • Increased condemnation of carcasses (up to 43%) at slaughter.

Multiple APEC serotypes have been associated with colibacillosis in poultry production; however, serotype O78 is considered the most relevant from the epidemiological perspective. APEC can lead to systemic infections either as a primary pathogen or as secondary infection to i) viral agents (e.g. Infectious Bronchitis, Newcastle Disease, Avian Influenza, Gumboro), ii) invasive bacteria such as Mycoplasma gallisepticum or iii) environmental stress conditioning bacterial entry through oral and respiratory routes (e.g. overcrowding, high level of dust and ammonia).2

A suitable vaccine against Colibacillosis should target multiple serotypes of E. coli.1 Regardless of the APEC serotype, a robust vaccination program is required to build immunity not only against APEC itself but also against viral and bacterial pathogens acting as primary infection.2

Product Details

Composition (before inactivation)

  • Inactivated Escherichia coli O166, O126, O157-H7, O18, O78, O127, and hemolytic un-typed ≥ 3x107.0 CFU/dose (from each strain).

Indications

For active immunization of commercial chickens to prevent air sac disease and septicaemia caused by avian colibacillosis.

Vaccination Program

Birds can be vaccinated from 2 weeks of age onwards, as per advice from your poultry veterinarian. Breeders and layers shall be vaccinated twice with 6 weeks interval.

Immunity

  • Onset of immunity: 4 weeks after primary vaccination.
  • Duration of immunity: until 8 weeks after single dose.

Dosage

The vaccine dose is 0.5 mL per bird.

Withdrawal

Zero days. 

Administration

Before use, the vaccine should be shaken well to ensure proper mixing. Sterile injection equipment should be used to avoid contamination. Do not use COLI-VAC™ if you notice critical irreversible separation of the emulsion. 

  • Subcutaneous injection: in the lower part of the neck. The needle should be inserted just under the skin in a direction away from the head and in a straight line with the neck.

Storage Precautions

  • Store and transport refrigerated (+2 °C to +8 °C).
  • Do not freeze.
  • Store in a dry place protected from direct light.
  • Do not use this product after the expiry date.
  • Shelf life after first opening the bottle: 3 hours.
COLI-VAC™

Presentation

COLI-VAC™ is packed and presented in 500 mL (1000 doses) polyethylene terephthalate (PET) bottles.

Download the Product Information Sheet

COLI-VAC™ product information sheet
Download

References

1. Ebrahimi-Nik et al 2018. Bacterial ghost of avian pathogenic E. coli (APEC) serotype O78:K80 as a homologous vaccine against avian colibacillosis. PLoS ONE 13(3): e0194888. https://doi.org/10.1371/journal.pone.0194888

2. Kathayat et al, 2021. Avian Pathogenic Escherichia coli (APEC): An Overview of Virulence and Pathogenesis Factors, Zoonotic Potential, and Control Strategies. Pathogens. 2021 Apr 12;10(4):467. doi: 10.3390/pathogens10040467.

3. Dho-Moulin & Morris Fairbrother, 1999. Avian pathogenic Escherichia coli (APEC). Veterinary Research, 1999, 30 (2-3), pp.299-316. HAL Id: hal-00902571.

4. Guabiraba & Schouler 2015. Avian colibacillosis: still many black holes. FEMS Microbiology Letters, 362, 2015, fnv118. doi: 10.1093/femsle/fnv118.

5. Mellata 2013. Human and avian extraintestinal pathogenic Escherichia coli: infections, zoonotic risks, and antibiotic resistance trends. Foodborne Pathog Dis. 2013 Nov;10(11):916-32. doi: 10.1089/fpd.2013.1533.

Boost Your Flock's Immunity against E. coli Infections

Fill out the form below to connect with Kemin's vaccine experts.

The content on this site is intended for informational purposes only and is not intended to be a substitute for professional veterinary advice. Although the information on this site is accessible worldwide, not all products or services are available to all persons or in all geographic locations or jurisdictions. Certain statements, product labeling and claims may differ by geography or as required by local governmental regulations.